American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6394)
  2. Solid Tumor Oncology Division (5535)
  3. Survivorship Research (1996)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1494)
  7. GSK Faculty (1388)
  8. Population Sciences Research Program (1379)
  9. Gastrointestinal Oncology Service (1352)
  10. Hematologic Malignancies, Division of (1277)
Search Within
Formats
  1. Meeting Abstract (6334)
  2. Journal Article (2582)
  3. Editorial (75)
  4. Review (66)
  5. Guidelines (54)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6394)
  2. Solid Tumor Oncology Division (5535)
  3. Survivorship Research (1996)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1494)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (275)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8694)
  2. JCO Precision Oncology (171)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (7)

More Publications

Results (9167)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results
    Meeting Abstract

    Herrmann, K.; Gafita, A.; De Bono, J. S.; Sartor, A. O.; Chi, K. N.; Krause, B. J.; Rahbar, K.; Tagawa, S. T.; Czernin, J.; El-Haddad, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study
    Meeting Abstract

    Shore, N. D.; Sieber, P. R.; Gleave, M.; De Giorgi, U.; Mehlhaff, B. A.; Danila, D. C.; Dunshee, C.; Lallas, C. D.; Pliskin, M.; Tang, Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PRO) in patients (pts) with BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study
    Meeting Abstract

    Rathkopf, D. E.; Roubaud, G.; Chi, K. N.; Efstathiou, E.; Attard, G.; Olmos, D.; Small, E. J.; Saad, M.; Castro, E.; Kim, W.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN)
    Meeting Abstract

    Beltran, H.; Dowlati, A.; Jain, P.; Johnson, M. L.; Sanborn, R. E.; Thompson, J. R.; Mamdani, H.; Schenk, E. L.; Aggarwal, R. R.; Sankar, K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Patel, M. R.; Choudhury, A. D.; Rasco, D. W.; Lakhani, N. J.; Hawley, J. E.; Aparicio, A.; Narayan, V.; Srinivas, S.; Runcie, K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations
    Meeting Abstract

    Zalcberg, J. R.; Blay, J. Y.; Chi, P.; Jones, R. L.; Serrano, C.; Somaiah, N.; Reichmann, W.; Sprott, K.; Cox, P.; Sherman, M. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Genomic profiling of bladder cancer in waterpipe and cigarette smokers: Implications for carcinogenicity and genetic landscape
    Meeting Abstract

    Shamseddine, A.; Abbas, N.; Chatila, W. K.; Walch, H. S.; Eichholz, J.; Schultz, N.; Solit, D. B.; Charafeddine, M.; Al Darazi, M.; Abou-Alfa, G. K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Multi-omic characterization of acquired resistance to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma
    Meeting Abstract

    Saad, E.; Labaki, C.; Miron, B.; Park, J.; Bakouny, Z.; Nassar, A.; Saliby, R. M.; Semaan, K.; Eid, M.; Meli, K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • First-line pembrolizumab plus lenvatinib for non-clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study
    Meeting Abstract

    Voss, M. H.; Gurney, H.; Atduev, V.; Suárez, C.; Climent, M. A.; Pook, D. W.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Nalbandian, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update
    Meeting Abstract

    Segal, N. H.; Girda, E.; Sohal, D.; Lakhani, N. J.; Olszanski, A. J.; Fong, L.; Han, H.; Casey, K. A.; Li, S.; Ganguly, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save